Journal Information
Original Article
Full text access
Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
Eileen M. Dunnea,
, Catia Cillonizb,c, Claire von Mollendorfd,e, Joseph Lewnardf,g,h, Lindsay R. Granta, Mary P.E. Slacki, Luis Jodara, Christian Theilackera, Bradford D. Gessnera
Corresponding author
a Pfizer Vaccines, Collegeville, PA, USA
b Faculty of Health Sciences, Continental University, Huancayo, Peru
c Department of Pneumology, Hospital Clinic of Barcelona, Barcelona, Spain
d Infection and Immunity, Murdoch Children's Research Institute, Parkville, VIC, Australia
e Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia
f Division of Epidemiology, School of Public Health, University of California, Berkeley, CA, USA
g Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley, CA, USA
h Center for Computational Biology, College of Engineering, University of California, Berkeley, CA, USA
i School of Medicine & Dentistry, Griffith University, Gold Coast Campus, QLD, Australia
Ver másArticle
This article is available in English
Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
Eileen M. Dunne, Catia Cilloniz, Claire von Mollendorf, Joseph Lewnard, Lindsay R. Grant, Mary P.E. Slack, Luis Jodar, Christian Theilacker, Bradford D. Gessner
10.1016/j.arbres.2022.12.015Arch Bronconeumol. 2023;59:157-64